Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Change in Account Payables came in at $2.1 million in Q1 2026, down 43.93% YoY from $3.7 million in Q1 2025, and down 53.16% on a QoQ basis from $4.4 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Change in Account Payables data on file, last reported at $2.1 million in Q1 2026.
- Quarterly Change in Account Payables fell 43.93% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.2 million (down 147.3% YoY) and the FY2025 annual result came in at -$2.6 million, down 140.65% from the prior year.
- Change in Account Payables eased to $2.1 million in Q1 2026, from $4.4 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $8.1 million in Q4 2024 to a low of -$5.9 million in Q3 2025.
- A 5-year average of $392294.1 and a median of $695000.0 in 2022 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 1488.73% — and 2024, when it jumped 2662.15%.
- Tracing RXRX's Change in Account Payables over 5 years: stood at $695000.0 in 2022, then tumbled by 145.61% to -$317000.0 in 2023, then jumped by 2662.15% to $8.1 million in 2024, then plunged by 45.59% to $4.4 million in 2025, then slumped by 53.16% to $2.1 million in 2026.
- The last three Change in Account Payables figures came in at $2.1 million (Q1 2026), $4.4 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.67 Mn |
| Jun 30, 2026 | -7.67 Mn |
| Mar 31, 2026 | 2.07 Mn |
| Mar 31, 2026 | 2.07 Mn |
| Dec 31, 2025 | 4.42 Mn |
| Dec 31, 2025 | 4.42 Mn |
| Sep 30, 2025 | -5.89 Mn |
| Sep 30, 2025 | -5.89 Mn |
| Jun 30, 2025 | -4.84 Mn |
| Jun 30, 2025 | -4.84 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 8.12 Mn |
| Dec 31, 2024 | 8.12 Mn |
| Sep 30, 2024 | -1.51 Mn |
| Sep 30, 2024 | -1.51 Mn |
| Jun 30, 2024 | -1.34 Mn |
| Jun 30, 2024 | -1.34 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.17 Mn |